CinCor Pharma Performance
| CINCDelisted Stock | USD 29.06 0.00 0.00% |
The firm shows a Beta (market volatility) of 1.81, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CinCor Pharma will likely underperform. CinCor Pharma right now shows a risk of 0.0%. Please confirm CinCor Pharma total risk alpha, downside variance, day median price, as well as the relationship between the maximum drawdown and skewness , to decide if CinCor Pharma will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CinCor Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, CinCor Pharma is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 26.1 M |
CinCor |
CinCor Pharma Relative Risk vs. Return Landscape
If you would invest 2,906 in CinCor Pharma on January 20, 2024 and sell it today you would earn a total of 0.00 from holding CinCor Pharma or generate 0.0% return on investment over 90 days. CinCor Pharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than CinCor, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CinCor Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CinCor Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CinCor Pharma, and traders can use it to determine the average amount a CinCor Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CINC |
Based on monthly moving average CinCor Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CinCor Pharma by adding CinCor Pharma to a well-diversified portfolio.
CinCor Pharma Fundamentals Growth
CinCor Stock prices reflect investors' perceptions of the future prospects and financial health of CinCor Pharma, and CinCor Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CinCor Stock performance.
| Return On Equity | -0.27 | |||
| Return On Asset | -0.15 | |||
| Current Valuation | 7.93 M | |||
| Shares Outstanding | 43.76 M | |||
| Price To Book | 1.02 X | |||
| EBITDA | (50.35 M) | |||
| Cash And Equivalents | 294.31 M | |||
| Cash Per Share | 7.80 X | |||
| Book Value Per Share | 11.86 X | |||
| Cash Flow From Operations | (30.85 M) | |||
| Earnings Per Share | (2.01) X | |||
| Total Asset | 141.11 M | |||
About CinCor Pharma Performance
To evaluate CinCor Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when CinCor Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare CinCor Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand CinCor Pharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents CinCor's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. Cincor Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 21 people.Things to note about CinCor Pharma performance evaluation
Checking the ongoing alerts about CinCor Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CinCor Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CinCor Pharma is not yet fully synchronised with the market data | |
| CinCor Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (50.37 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CinCor Pharma currently holds about 294.31 M in cash with (30.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.8. | |
| Over 94.0% of the company shares are held by institutions such as insurance companies |
- Analyzing CinCor Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CinCor Pharma's stock is overvalued or undervalued compared to its peers.
- Examining CinCor Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CinCor Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CinCor Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CinCor Pharma's stock. These opinions can provide insight into CinCor Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in CinCor Stock
If you are still planning to invest in CinCor Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CinCor Pharma's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |